Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › cabozantinib

cabozantinib

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of cabozantinib

33 trials tracked of cabozantinib: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 247 citations.

33Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 28 Phase 1 2 Other / NA 1
  1. Phase 3 Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 Completed · 247 cited
  2. Phase 3 Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy Completed · 58 cited
  3. Phase 2 Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer Completed
  4. Phase 2 A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer Completed
  5. Phase 2 Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer Completed
  6. Phase 2 Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors Completed
Show 27 more trials
  1. Phase 2 A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases Completed
  2. Phase 2 Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases Completed
  3. Phase 2 Study of Cabozantinib (XL184) in Adults With Advanced Malignancies Completed
  4. Phase 2 Cabozantinib and Nivolumab for Carcinoid Tumors Completed
  5. Phase 2 A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma Completed
  6. Phase 2 Cabozantinib for Adults With Advanced Soft Tissue Sarcoma Completed
  7. Phase 2 Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer Completed
  8. Phase 2 An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer Completed
  9. Phase 2 Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma Completed
  10. Phase 2 Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors Completed
  11. Phase 2 Cabozantinib in Advanced Solid Malignancies Completed
  12. Phase 2 Cabozantinib in Patients With Hepatocellular Carcinoma (ACTION) Completed
  13. Phase 2 Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma Completed
  14. Phase 2 Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma Completed
  15. Phase 2 Cabozantinib for Metastatic Triple Negative BrCa Completed
  16. Phase 2 CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma Completed
  17. Phase 2 Cabozantinib and Pembrolizumab in Metastatic Pancreas Completed
  18. Phase 2 Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer Completed
  19. Phase 2 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Completed
  20. Phase 2 Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer Completed
  21. Phase 2 Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Completed
  22. Phase 2 Cabozantinib for Advanced Urothelial Cancer Completed
  23. Phase 2 A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma Completed
  24. Phase 2 Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma Completed
  25. Phase 1 A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer Completed
  26. Phase 1 Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer Completed
  27. N/A Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma Completed

Showing the 33 most-cited and recently-updated of 33 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Selpercatinib tops cabozantinib and vandetanib for PFS in advanced medullary thyroid cancer
Diabetes & Endocrinology Meta-analysis
Selpercatinib tops cabozantinib and vandetanib for PFS in advanced medullary thyroid cancer Selpercatinib Shows Better Survival for Advanced Medullary Thyroid Cancer
A network meta-analysis of 1,076 patients with advanced medullary thyroid cancer found selpercatinib superior to cabozantinib and vandetanib…
A new analysis of 1,076 patients suggests selpercatinib may offer better progression-free survival than other treatments for medullary thyro…
Frontiers Jun 22, 2026
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
Oncology FDA Approval
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
FDA May 15, 2026